1. Scrip
  2. >>Business
  3. >>Deals

$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform

Masking Technology Could Address Safety Limitations Of Solid Tumor Candidates

 
• By Ayisha Sharma

The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.

Handshake of businessmen

Sanofi is to pay $1bn up front to acquire privately held biotech Amunix Pharmaceuticals, Inc., which is developing products designed to overcome safety issues that have hampered the development of T-cell engager therapeutics in solid tumors. Amunix could also receive up to $225m upon reaching certain development milestones. The deal rides the wave of several bolt-on acquisitions made by the French big pharma group in 2021.

Mountain View, CA-headquartered Amunix specializes in developing T-cell engagers (TCEs) and cytokine therapies for cancer, having decided to build its own pipeline after initially focusing on licensing out its technology to extend the half-life of and mask different types of therapeutic molecules until they reach their target. Sanofi and Swedish Orphan Biovitrum AB use the technology in their hemophilia A asset BIVV 001 that the former gained through its acquisition of Biogen, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.